Touch Medical Media coverage of data presented at EADV 2021:
It was a pleasure to speak with Dr Andy Blauvelt (Oregon Medical Research Center, Portland, OR, USA) about the results from the recent open-label study investigating the efficacy and safety of switching from dupilumab to upadacitinib in the treatment of atopic dermatitis.
His presentation entitled ‘Efficacy and Safety of Switching from Dupilumab to Upadacitinib in Moderate-to-Severe Atopic Dermatitis: Results from an Open Label Extension Trial’ was given at the EADV 30th Congress, 29 Sep – 2 Oct.
Questions
- Could you give us a brief overview of dupilumab and upadacitinib, their mechanisms of action and their means of administration? (0:15)
- What is the rationale for switching from dupilumab to upadacitinib in the treatment of moderate-to-severe atopic dermatitis? (1:26)
- Could you tell us a little about the methodology of your clinical trial? (2:15)
- What were the findings of the open-label extension study and what are their clinical implications? (2:55)
- How likely is it in the future that upadacitinib will replace dupilumab as first-line treatment of moderate-to-severe atopic dermatitis? (4:23)
Disclosures: Dr Andy Blauvelt has served as a scientific adviser and/or clinical study investigator for AbbVie, Abcentra, Aligos, Almirall, Amgen, Arcutis, Arena, Aslan, Athenex, Boehringer Ingelheim, Bristol-Myers Squibb, Dermavant, Eli Lilly and Company, Evommune, Forte, Galderma, Incyte, Janssen, Landos, Leo, Novartis, Pfizer, Rapt, Regeneron, Sanofi Genzyme, Sun Pharma, UCB Pharma, and Vibliome.
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Matthew Goodwin.
Filmed in coverage of the EADV’s 30th Congress, 29 Sep – 2 Oct 2021.
This content was developed by Touch Medical Media and is not affiliated with the European Academy of Dermatology & Venereology (EADV) or the congress.
